We are planning to present the interim data from the trial in both the triple-negative breast cancer cohort and the HER2 cohort at that meeting in the first week of December. So the change right now is gathering the information and working on the plan to move forward with this presentation.
It was during the Monday call. Lots of the things I had trouble hearing because of the accents or because I was distracted by the price changes. They confirmed this timeline in the transcript from the Monday call.